Table 1.
Parameters for mavrilimumab, efalizumab, and romosozumab, based on fits to data
| Mavrilimumab | Efalizumab | Romosozumab | Units | |
|---|---|---|---|---|
| Weight‐based dose | 10 | 10 | 10 | mg/kg |
| Equivalent molar dose | 4667 | 4667 | 4667 | nmol |
| V c | 2.8 | 2.4 | 2.4 | L |
| V p | 5.6 | 3.6 | 2.6 | L |
| Cl | 0.3 | 0.46 | 0.25 | L/d |
| Q | 1.7 | 9.7 | 0.54 | L/d |
| k syn = V max/V c | 2.4 | 8.5 | 6.1 | nM/d |
| K ss = KM | 1.1 | 1.2 | 12 | nM |
| k e(R) | 2.2 | 4400 | 860 | 1/d |
| k e(CR) | 2.2 | 4400 | 860 | 1/d |
| k off | 10 | – | – | 1/d |
| k on = (k off + k e(CR))/K ss | 11 | – | – | 1/(nM · d) |
Cl, clearance; k e(C), drug elimination rate; k e(R), receptor elimination rate; KM, Michaelis‐Menten constant; k off, dissociation rate; k on, association rate; Kss, quasi‐steady‐state constant; k syn, receptor synthesis rate; Q, intercompartmental clearance; V c, central volume; V max, maximal rate of saturable (nonlinear) elimination; V p, peripheral volume.